Our core technology is centered on synthesizing and formulating ketone precursors for therapeutic purpose to address metabolic defects in neurological disorders
By combining the deep scientific expertise of our team with a team with deep clinical operations experience, we can accelerate the way medicines are traditionally discovered and developed. Cerecin is leading the research to develop novel formulations for lipid based therapeutics, such as our lead asset CER-0001 (tricaprilin). This includes development of proprietary method of synthesis and analytical methods to develop & test ultrapure composition of CER-0001. Our novel Lipid in NanoEmulsion (LINE) technology aims to improve bioavailability and produce preservative-free drug products.
Reliable and precise induction of ketosis
Cerecin has developed a novel, proprietary technology and method of synthesis which results in an ultrapure version of tricaprilin. Ultrapure tricaprilin contains low levels of impurities commonly found in other oils. Cerecin’s ultrapure tricaprilin exceeds recent EU and US guidance on impurities in processed oils. The development of these methods and materials reflects Cerecin’s commitment to the highest standards of the pharmaceutical industry.
lipid in nanoemulsion (LINE)
Cerecin utilizes its lipid in nanoemulsion (LINE) core technology to develop a series of formulated versions of lipid-based therapeutics. Nanoemulsions distinguish themselves by possessing smaller droplet diameters spanning from approximately 20 to 200 nm. The reduced dimensions of these droplets endow them with numerous potential advantages over conventional emulsions, specifically in certain applications. These advantages encompass enhanced stability and increased surface area of encapsulated compounds to facilitate the actions of digestive enzymes.
CER-022 is a radiolabeled ketone body that is being investigated for the use in quantifying regional ketone metabolism. CER-022 is analogous to 18F FDG PET which is used to quantify regional glucose metabolism. Just as FDG PET has broad use in diverse fields such as oncology and neurology to undercover disturbances in glucose metabolism, FBHB PET is being investigated for broad applications in many areas related to ketone body metabolism. The technology has been licensed in and being collaboratively developed with the University of Alberta.